Jorge Salinas
Stanford University · Rheumatology
Active 1982–2024
About
Jorge Salinas is an Assistant Professor of Medicine specializing in Infectious Diseases at Stanford University. He is affiliated with the Center for Artificial Intelligence in Medicine & Imaging (AIMI), where his work focuses on integrating artificial intelligence into healthcare, particularly in infectious diseases. His research involves leveraging AI technologies to improve diagnosis, treatment, and patient outcomes in infectious diseases, contributing to the advancement of medical imaging and data-driven healthcare solutions.
Research topics
- Internal medicine
- Medicine
- Oncology
- Environmental science
- Mechanical engineering
- Physics
- Oceanography
- Urology
- Immunology
- Engineering
- Pathology
- Geology
Selected publications
ICE volume 44 issue 8 Cover and Front matter
Infection Control and Hospital Epidemiology · 2023
- Environmental science
- Geology
- Engineering
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Annals of Oncology · 2023 · 379 citations
- Medicine
- Internal medicine
- Oncology
BACKGROUND: Amivantamab plus carboplatin-pemetrexed (chemotherapy) with and without lazertinib demonstrated antitumor activity in patients with refractory epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) in phase I studies. These combinations were evaluated in a global phase III trial. PATIENTS AND METHODS: A total of 657 patients with EGFR-mutated (exon 19 deletions or L858R) locally advanced or metastatic NSCLC after disease progression on osimertinib were randomized 2 : 2 : 1 to receive amivantamab-lazertinib-chemotherapy, chemotherapy, or amivantamab-chemotherapy. The dual primary endpoints were progression-free survival (PFS) of amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy. During the study, hematologic toxicities observed in the amivantamab-lazertinib-chemotherapy arm necessitated a regimen change to start lazertinib after carboplatin completion. RESULTS: All baseline characteristics were well balanced across the three arms, including by history of brain metastases and prior brain radiation. PFS was significantly longer for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy [hazard ratio (HR) for disease progression or death 0.48 and 0.44, respectively; P < 0.001 for both; median of 6.3 and 8.3 versus 4.2 months, respectively]. Consistent PFS results were seen by investigator assessment (HR for disease progression or death 0.41 and 0.38 for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy, respectively; P < 0.001 for both; median of 8.2 and 8.3 versus 4.2 months, respectively). Objective response rate was significantly higher for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy (64% and 63% versus 36%, respectively; P < 0.001 for both). Median intracranial PFS was 12.5 and 12.8 versus 8.3 months for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy (HR for intracranial disease progression or death 0.55 and 0.58, respectively). Predominant adverse events (AEs) in the amivantamab-containing regimens were hematologic, EGFR-, and MET-related toxicities. Amivantamab-chemotherapy had lower rates of hematologic AEs than amivantamab-lazertinib-chemotherapy. CONCLUSIONS: Amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy improved PFS and intracranial PFS versus chemotherapy in a population with limited options after disease progression on osimertinib. Longer follow-up is needed for the modified amivantamab-lazertinib-chemotherapy regimen.
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
Journal of Clinical Oncology · 2023 · 312 citations
- Medicine
- Internal medicine
- Oncology
PURPOSE: alterations, can sensitize cancer cells to poly (ADP-ribose) polymerase inhibition, which may improve outcomes in treatment-naïve mCRPC when combined with androgen receptor signaling inhibition. METHODS: subgroup and then in the full HRR+ cohort, with secondary end points analyzed for the full HRR+ cohort if rPFS was statistically significant. A futility analysis was preplanned in the HRR- cohort. RESULTS: = .022). These findings were supported by improvement in the secondary end points of time to symptomatic progression and time to initiation of cytotoxic chemotherapy. In the HRR- cohort, futility was declared per the prespecified criteria. Treatment with niraparib + AAP was tolerable, with anemia and hypertension as the most reported grade ≥ 3 adverse events. CONCLUSION: Combination treatment with niraparib + AAP significantly lengthened rPFS in patients with HRR+ mCRPC compared with standard-of-care AAP. [Media: see text].
Journal of Infection · 2022 · 64 citations
- Medicine
- Internal medicine
- Immunology
Frequent coauthors
- 180 shared
Daniel J. Diekema
University of Iowa
- 152 shared
Alexandre R. Marra
- 130 shared
Takaaki Kobayashi
University of Iowa Hospitals and Clinics
- 128 shared
Curtis J. Donskey
Geriatric Research Education and Clinical Center
- 127 shared
David P. Calfee
Communities In Schools of Orange County
- 127 shared
Jennifer L. Cadnum
Louis Stokes Cleveland VA Medical Center
- 126 shared
Tara N. Palmore
New York Proton Center
- 125 shared
Jon P. Furuno
University of Pittsburgh
Education
- 2006
MD
Universidad Nacional Mayor de San Marcos Facultad de Medicina de San Fernando
Similar researchers at Stanford University
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Jorge Salinas
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup